# Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

> **NCT00949182** · PHASE2 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 20 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00949182
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949182, "Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00949182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*